ACRX News and Press, AcelRx Pharmaceuticals Inc. From 03/14/23

AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals PR Newswire Agreement with Alora Pharmaceuticals provides AcelRx with 15% royalties on commercial sales, 75% royalties on Department of Defense (DoD) sales, up to $116.5 million in potenti...

AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures PR Newswire Study is the first to report on the use of DSUVIA® in the rapidly growing field of rhinology where otolaryngologists are performing painful...

Pain therapy developer AcelRx Pharmaceuticals ( NASDAQ: ACRX ) announced plans sell ~$7.5M worth of registered direct offering of common stock and warrants on Tuesday, sending its shares ~3% lower in the pre-market. The deal with an unnamed life sciences-focused investment fund in...

AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock PR Newswire HAYWARD, Calif. , Dec. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company foc...

AcelRx Pharma ( NASDAQ: ACRX ) is trading ~8% higher aft er its sublingual sufentanil tablets for post-operative pain management showed lower pain scores, fewer rescue doses and had a shorter hospital stay in patients compared to those receiving continuous femoral nerve block. ...

AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine PR Newswire Patients reported lower pain scores, required fewer rescue doses and ...

AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2022 Results Earnings Conference Call November 14, 2022, 04:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and Co-Found...

AcelRx Pharmaceuticals press release ( NASDAQ: ACRX ): Q3 GAAP EPS of -$0.94 beats by $0.26 . Revenue of $0.51M (-72.6% Y/Y) misses by $0.12M . Initial Niyad development batch successfully produced; preparations on track for an Emergency Use Authorization ...

AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Initial Niyad development batch successfully produced; preparations on track for an Emergency Use Authorization submission DSUVIA sales of $0.5M...

AcelRx Pharmaceuticals ( NASDAQ: ACRX ) is scheduled to announce Q3 earnings results on Monday, November 14th, after market close. The consensus EPS Estimate is -$1.20 and the consensus Revenue Estimate is $0.63M (-66.1% Y/Y). Over the last 3 months, EPS estimates have...